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Abstract 
Background. The surgical advancements in orthotopic heart transplantation along with 
improvements in immunosuppressive drugs increase the survival rate and quality of life of heart 
transplant recipients. However, the prolonged use of immunosuppressive medications increases 
the risk of infection and related cancer. Solid organ transplant recipients have approximately two 
to three-fold higher risk of developing de novo cancers. Thus, modulation of immunosuppression 
regimen and cancer screening appear as key factors in preventing and treating de novo cancer 
among solid organ transplant recipients.  
Purpose: The purpose of this project was to examine the effectiveness of multiple follow-up 
phone calls after clinic visits as an intervention to enhance compliance with cancer surveillance 
in adult heart transplant recipients. 
Methods: The convenience sample of consenting participants (n= 41) was randomly divided into 
intervention (n = 21) and control (n=20) groups.  The intervention group received multiple 
follow-up phone calls at designated time intervals after a clinic visit to reinforce compliance with 
cancer screening.  The control group continued to receive routine care.  
Results: The intervention resulted in a significant statistical difference (χ2 (1) = 4.062, 
p=0.044<.05) between the control and the intervention groups for timely cancer screening. The 
intervention group had a 50% follow-up with a specialist compared to the 15% follow up-rate of 
the control group.  
Conclusion:  A nurse practitioner-led multiple follow-up phone calls was effective in increasing 
de novo cancer screening among adult heart transplant recipients. 
Keywords: solid organ transplantation, immunosuppression, de novo cancer, follow-up 
phone calls.
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De Novo Cancer Monitoring for Adult Heart Transplant Patients to Improve Early Detection and 
Intervention 
Introduction 
Organ transplantation is currently being utilized increasingly as a treatment for an 
otherwise end-stage fatal organ disease. The advances in surgical techniques and improvements 
in anti-rejection medications prolong the survival of the solid transplant organ recipients (Piselli 
et al., 2014).  However, the chronic use of immunosuppressive medications increases the risk of 
opportunistic diseases, particularly infections and virus-related malignancies (Piselli et al., 
2014).  Malignancy has become one of the three major causes of death after transplantation; the 
overall incidence of cancer is increased two to three-fold in solid organ transplant recipients 
compared to the general population (Albugami et al., 2014; Chapman et al., 2013).  Despite the 
increase in cancer-related incidents among solid organ transplant recipients, studies show that 
cancer screenings are not routinely done (Turkeli et al., 2016). Once the solid organ recipients 
who are chronically immunosuppressed are diagnosed with full-blown cancer, the mode of 
treatments and its ill effects are almost always very difficult, expensive and potentially 
deadly.  According to Katabathina et al. (2015), management strategies which can improve 
malignancy-related morbidity and mortality in transplant recipients include prevention of risk 
factors, appropriate modulation of immunosuppressive agents, prophylaxis against infection-
related malignancies, and use of intensive targeted screening programs.  Thus, there is an 
essential need for different health care providers of solid organ transplanted recipients to tailor a 
specific type of surveillance and thorough evaluation for early recognition of de novo (newly 
developed) cancer to avoid full-blown cancer in already complicated health status.   
Background  
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According to the United Network for Organ Sharing (UNOS) (2018), in the United States 
alone, there were a total of 34,768 organ transplants in 2017; the national data of the transplanted 
organs from January 1, 1988, to February 15, 2018, was 724,356,  and of those heart transplants 
totaled to about 10%  (Appendix A). Organ transplantation is currently being utilized 
increasingly as a treatment for an otherwise end-stage fatal organ disease. For patients who are 
living with the most advanced heart failure, orthotopic heart transplantation (OHT) provides a 
means of significantly improving the quality of life; proved to be clinically useful, life-saving 
and cost-effective (Linden, 2009). Transplant recipients are living better and longer lives due to 
surgical advancements and improvements in immunosuppressive drugs. However, prolonged 
exposure to immunosuppression increases the risk of de novo cancer among these patients 
(Piselli et al., 2014). A common thread from the literature is that too much immunosuppression 
decreases the ability of the immune system to fight against different oncogenic events and thus 
expose the patient to increased risks of de novo cancer development (Acuna et al., 2017; 
Albugami et al., 2014; Chapman et al., 2013; Collins et al., 2012).  A likely explanation of the 
predisposition for de novo malignancy among solid organ recipients (e.g.., heart) is that 
immunosuppression impairs the immune surveillance of virus-transformed cells by the body, and 
thus increases the frequency of virus infection (Vial & Descotes, 2003). 
Cancer incidence increases with time following heart transplantation: one year (2.6%), 
five years (14.1%), and ten years (27.9 %) (Lund et al., 2013). Youn et al. (2018) supported these 
stating that the risk of any de novo solid malignancy between years one and five after 
transplantation was 10.7% — skin cancer (7.0%), non-skin solid cancer (4.0%), and 
lymphoproliferative disorders (0.9%). Youn et al. (2018) also further stipulated that patients who 
had developed de novo malignancy have increased mortality compared to those who did not.  
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The literature search showed at least a two to three-fold increase for malignancy 
development among solid transplant recipients compared to the general public (Albugami & 
Kiberd, 2014; Chapman et al., 2013).  A cohort study by Engels et al. (2011) utilizing linked data 
from the United States Scientific Registry of Transplant recipients from 1987 to 2008 and 13 
state/regional cancer registries reported a 1,374.7 incidence per 100,000 or a 6.1% de novo 
malignancy (10,656 out of 175,732) during follow up, corresponding to an overall doubling 
cancer risk compared to the general public.  The U.S. based study by Engels et al. (2011), 
observed a broad spectrum of cancer risk including numerous infections related and unrelated 
malignancies.  The infection-related malignancies noted are as follows in decreasing order:  non-
Hodgkin's lymphoma, liver, stomach, Kaposi's sarcoma, oropharynx including the tonsils, anus, 
Hodgkin lymphoma, vulva, cervix, penis, nasopharynx, and vagina (Engels et al., 2011). The risk 
for infection-unrelated malignancies was also significantly elevated for cancers. In decreasing 
order, the infection-related cancers are as follows: the lung, prostate, kidney, colorectum, breast, 
melanoma, thyroid, urinary bladder, skin and pancreas, other oral cavity and pharynx, lip, plasma 
cell neoplasms, acute myeloid leukemia, larynx, esophagus, uterine corpus, soft tissue including 
heart, salivary gland, ovary, small intestine, brain, testis, other biliary, intrahepatic bile duct, 
chronic myeloid leukemia, chronic lymphocytic leukemia, gallbladder, eye and orbit, renal, 
pelvis, acute lymphocytic leukemia, mesothelioma, bones and joints, and those that were 
grouped as other unspecified malignancies, miscellaneous specified malignancies, or tumors with 
poorly specified histology (Engels et al., 2011).  Later studies by Acuna et al. (2017) supported 
the above statement affirming that the incidence of de novo malignant growth varies with 
different organs — breast, prostate, ovarian and brain cancers have fewer incidents with the de 
novo development of cancer compared to lung, colon, melanoma, liver cancers and lymphoma. 
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Chapman et al. (2013) also found that depending on which solid organ was transplanted, the 
areas where the de novo cancer grew varied in sites, frequency, aggression, and overall fatal 
outcome.  
Despite the higher frequency of cancer among solid organ transplant recipients, studies 
showed that (1) cancer screenings are not routinely done, and (2) early identification of cancer 
diagnosis leads to improved survival (Turkeli et al., 2016). Management strategies that can 
improve malignancy-related morbidity and mortality in transplant recipients (e.g. heart 
transplant) include prevention of risk factors, appropriate modulation of immunosuppressive 
agents to maintain a balance between avoidance of rejection and cancer prevention; prophylaxis 
against infection-related malignancy, and the use of intensive targeted screening programs 
(Katabathina et al., 2015).   
Heart transplant recipients receive life-saving and ameliorating therapy. However, 
complications are common and vary in severity from mild to fatal (Alba et al., 2016).  The most 
frequent complications of heart transplantation included cellular or antibody-mediated rejections, 
cardiac allograft vasculopathy, graft dysfunction, chronic kidney disease, infection, and, of 
course, malignancy.   
There is no standard recommendation for the different solid transplanted organs in 
monitoring de novo malignancy (Acuna et al., 2017). As a result, a critical need exists for an 
evidenced-based best practice screening, which is tailored to the individual patient’s history that 
may include prior malignancy, family history of cancer , co-morbidities post-transplantation and 
the likelihood of de novo cancer development (Acuna et al., 2017; Albgami et al., 2014; Collins 
et al., 2012; Inamoto et al., 2015; Katabathina et al., 2015; Turkeli et al., 2016).  
Problem Statement 
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The critical importance of addressing de novo cancer development among adult heart 
transplant recipients is indicated by findings that post solid organ transplantation (e.g., heart 
transplant recipients) develop a two to three-fold increased risk of de novo malignancy compared 
to the general public due to long-term use of immunosuppressant medications. 
Organization “Gap” Analysis of the Project Site 
The site of the DNP project was the out-patient clinic area in one of the major hospitals in 
New York City.   The patients who are seen in this center are adult individuals with a primary 
diagnosis of advanced cardiac conditions such as advanced heart failure, Left Ventricular Assist 
Device (LVAD), and heart transplant. Ten transplant cardiologists are working in this center and 
ten adult nurse practitioners.  Five out of 10 nurse practitioners, including the student, are heart 
transplant providers. 
At the selected site, there is no specific written protocol or guideline as to when the adult 
heart transplant recipients should follow up with other relevant specialists for early cancer 
screening and intervention. There is an implied understanding among the heart transplant 
providers of the need for a specialist follow up outside cardiology. However, the implementation 
of such is inconsistent and varies from one provider to another.  At the time of the patients’ clinic 
visits, the patients are reminded of their immunosuppression status, which increases the risk of 
de novo cancer development and therefore the need for a cancer screening follow up.  However, 
after such patient teaching/education, there is no further follow-up from the transplant team once 
they go home and until the next clinic visit. Due to the many complicated issues that heart 
transplant patients have to deal with, they are often too busy to schedule their cancer screenings. 
It is often postponed to later dates, and sometimes never performed.  The farther stable heart 
transplant patients are from their transplant dates, the longer is their return date for clinic follow 
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up. Sometimes, these stable patients are seen every six months or more. This generates concerns 
since the longer patients take immunosuppressive medications, the higher is their likelihood of 
developing de novo malignancy (Alba et al., 2016; Lund et al., 2013; Piselli et al., 2014; Youn et 
al., 2018). If they did not have any screening, de novo cancer may have developed before the 
next visit.  The lack of an explicit and specific guideline or policy at this particular site regarding 
de novo cancer development screening among adult heart transplant recipients indicates a “gap” 
in evidenced based-practice as recommended by current studies noted in the literature. 
Literature Review 
Search Method 
A comprehensive search of the literature for evidence regarding adult heart 
transplantation de novo malignancy development and cancer screening care after heart 
transplantation was completed. The review of the literature was conducted to identify the current 
literature and practices in solid organ transplantation about the incidence of de novo cancer 
malignancy and the role of screening without focusing necessarily on disease management of 
adult heart transplant patients. The following databases were used: CINAHL Complete, JSTOR, 
Science Direct, Cochrane Library, and Google Scholar. Search terms included: transplantation, 
solid organ transplantation; heart transplantation, cardiac transplantation; cancer 
or malignancy screening, de novo cancer; follow up phone calls, reminder systems to improve 
adherence, motivating patients with multiple phone calls.  
Search Results 
In PubMed, there was no definition offered under MeSH for “solid organ  
transplantation.” However, if the word "solid" was removed, the remaining terms “organ 
transplantation” was defined as transference of an organ between individual of the same species 
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or between individual of different species. The literature review was solely focused on organ 
transplantations from human to human.  Utilizing the PubMed Search Builder using the phrases 
“de novo cancer screening in organ transplantation” yielded 34 citations. Malignancy was 
defined within the PubMed MeSH term as new abnormal growth of tissue. Malignant neoplasm 
shows a higher degree of anaplasia and has the properties of invasion and metastasis, compared 
to a benign tumor.  
“De novo cancer” or “malignancy” within PubMed Mesh term did not offer any 
definition.  In CINAHL Complete, the terms “cancer screening” and “organ transplantation” 
were again entered in two fields, which yielded 43 citations. In JSTOR the same phrases were 
utilized with the addition of “Health Sciences” as a limiting factor which yielded 22 citations. In 
Science Direct, the “Expert Search” was utilized using the same phrases as above with further 
qualifiers limited: “transplant recipients” yielding 33 results after removal of duplicates. A total 
of 132 articles were retrieved from the databases mentioned above. 
Review of the above literature did not include any specific articles about heart 
transplantation and followed up care for screening of de novo malignancy. Therefore, the 
DNP student expanded the search to include the following terms: follow-up phone calls, 
reminder systems to improve adherence, motivating patients with multiple phone calls.  At this 
time, in CINAHL utilizing the Advanced Search: "telephone follow-up calls" rendered 226 
results; with the addition of inclusion criteria only to include: English Language, Adults, and 
Nursing, from 2010-2018, the search rendered six articles. In the advanced search of JSTOR, 
using the terms "follow up phone calls" and "clinic discharge," the search yielded 25 articles 
from 2010 to 2018.  In Cochrane Library: Medical Terms (MeSH): Reminder Systems and 
Nursing as subheadings exploded all trees; the systematic reviews of Cochrane Database 
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included 22 articles. The above articles obtained from the database searches were critically 
reviewed for relevance and reliability using The John Hopkins Nursing Evidence-Based Practice 
Rating Scale (Newhouse, Dearholt, Poe, Pugh, & White, 2005) leaving a total of 28 articles only, 
deemed to be 1A and 1B. 
Synthesis 
For patients who are living with severe advanced heart failure, orthotopic heart 
transplantation (OHT) provides a means of significantly improving the quality of life in patients 
with end-stage heart failure (Linden, 2009).  Solid organ transplant recipients need 
immunosuppressive drugs to avoid rejection of their transplanted heart. However, chronic 
exposure to chronic immunosuppression state decreases the ability of the immune system to fight 
against oncogenesis, and thus exposing the patient to increased risks of de novo cancer 
development (Acuna et al., 2017; Albugami et al., 2014; Chapman et al., 2013; Collins et al., 
2012). 
The literature search reiterated the importance of regular screening many times to reduce 
the burden of cancer development among solid organ recipients (Acuna et al., 2017; Albgami et 
al., 2014; Collins et al., 2012; Inamoto et al., 2015; Katabathina et al., 2015; Turkeli et al., 2016). 
There is no one kit, tool or recommendation for all solid transplanted organs for the monitoring 
of de novo malignancy (Acuna et al., 2017); nevertheless, a critical need exists for an evidenced-
based screening tailored to an individualized type of surveillance (Acuna et al., 2017; Albgami et 
al., 2014; Collins et al., 2012; Inamoto et al., 2015; Katabathina et al., 2015; Turkeli et al., 2016). 
The evidenced-based intervention for this study is the utilization of follow-up phone calls 
among adult heart transplant recipients. During the literature search, the DNP student did not 
find any study regarding follow-up phone calls for cancer screening specific to heart transplant 
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recipients or any solid organ recipients for that matter. However, there were significant numbers 
of studies for best practice guidelines regarding follow up phone calls to promote the transition 
of care among hospital discharged patients. Such studies noted that follow-up phone calls 
resulted with positive effects such as increased patient satisfaction, decreased patient’s anxiety, 
reduced emergency room or hospital re-admissions, and, importantly, improved adherence with 
the plan of care, (Biese et al., 2014; Dudas et al., 2001; Fenerty et al., 2012;  Harrison et al., 
2011). Based on these findings, it is then possible to apply this same principle and utilize the 
intervention of a follow-up phone call to obtain similar positive results for the purpose of this 
project. 
 A study by Biese et al. (2014) showed that a telephone call expedited the follow up of 
older patients discharged from the emergency department with their primary care physicians. 
Adherence of patients to follow-up with other providers plays a crucial role in medical 
surveillance of chronic diseases (Lin & Wu, 2014).  As providers amidst times of significant 
budgetary cuts, nurse practitioners are positioned uniquely to conduct telephone follow-up calls 
for continuity of care, especially to those vulnerable populations (Hannan, 2012). For select 
complex patients with extensive and complicated discharge plans, ideal post-discharge care may 
require more intensive interventions such as repeated phone calls by a clinician or home visits 
(Burke & Coleman, 2013; Soong et al., 2014).  According to Dudas et al. (2001), post- discharge 
follow-up phone calls can identify essential opportunities for intervention, which can prevent 
future issues. The compelling results of follow-up phone calls were confirmed many times by 
later studies. A Cochrane systematic review examining the effects of follow-up phone calls on 
patient outcomes found some evidence of improved aftereffects such as adherence to post-
discharge appointments without evidence of adverse events (Mistiaen & Poot, 2006; Soong et al., 
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2014). Telephone follow-up plays an important role where information can be reinforced thereby 
increasing compliance (Beaver, Twomey, Witham, Foy, & Luker, 2006). Telephone follow-up 
intervention also reduces the number of health problems post-discharge, decreases the frequency 
and intensity of issues; furthermore, patients consider the information they received from the 
telephone follow up as valuable (Clari et al., 2015). Studies showed that patients with poor health 
benefited from the follow-up after hospital discharge, which could prevent an unnecessary 
burden on the community health system (Clari et al., 2015). Findings generally showed that early 
follow-up after hospital discharge was associated with improved patient outcomes (Zierler, 
2017). 
A systematic review and meta-analysis by Lin and Wu (2014) regarding the impact of 
short message service (SMS) or text messaging versus telephone reminders on the follow-up rate 
of patients concluded that SMS and telephone reminders could both significantly improve the 
follow-up rate of patients towards their plan of treatment. However, telephone reminders were 
more effective with a higher risk of bias compared to that of the SMS reminders. According to 
Lindsay (2003), telephone follow-up may be considered a socially complex intervention 
characterized by actions that are difficult to define and control, contain many contextual factors, 
and can vary from one patient to another. Studies have indicated the importance of a nurse-led 
follow up with patients (Young et al., 2013). Patients were satisfied to discuss sensitive 
issues over the phone (Beaver et al., 2006) and were not only receptive to but actively wanted 
such intervention as an addition to their health care (Cox & Wilson, 2003).  
There are different ways to provide a person-centered follow up. A face-to-face approach 
would seem to be more effective, however, could be considered time-consuming, and more 
expensive for the patients; thus, less feasible given the economic climate (Clari et al., 2015). 
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Telephone follow-up can be an excellent way to provide health education on managing 
symptoms, recognizing complications earlier, and giving patient reassurance (Calijo & 
Hogendorf-burgers, 2010; Cox et al., 2003; Hartford, 2005).  Different studies as noted earlier 
showed that patients with varying diagnoses benefited from telephone follow-up. This may be 
related to the fact that patients have the opportunity to ask further questions, or that the clinicians 
may be able to reinforce the contents of the care plan. As a result, the economical and effective 
intervention of a follow-up phone call ensured increased patients’ satisfaction, proved to have 
fewer hospital re-admissions, and promoted better patients’ compliance regarding their discharge 
instructions (Biese et al., 2014; Dudas et al., 2001; Fenerty et al., 2012; Harrison et al., 2011). 
Conceptual Framework 
The conceptual framework that the DNP student used for this project was the Self Care 
Deficit theory by Dorothy E. Orem (Appendix B). The Theory of Self Care posits that patients 
need to initiate self-care related activities to maintain health and well-being (Orem, 1997). The 
DNP student has always been a proponent that patients should take ownership of their health. A 
study by Hibbard and Greene (2013) showed rising evidence that patients who are more 
activated or involved in their care obtain better results and care experiences. Interventions and 
policies therefore aimed at promoting and establishing the patients' role in managing their health 
care should be measured (Hibbard & Greene, 2013). This DNP project intends ultimately to 
implement a practice change policy that would encourage a self-care response geared explicitly 
toward early cancer screening among adult heart transplant recipients at the project site. 
Methods  
Project Site and Population 
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The project site was in one of the advanced cardiac care out-patient clinics in an urban 
area. The stakeholders were the Medical Director of the Heart Failure, LVAD, and Heart 
Transplant Program; and the adult heart transplant cardiologists. 
The study populations were the adult heart transplant recipients who came for their clinic 
visit. These patients were randomly selected from the caseload of the DNP student. The inclusion 
criteria included (1) > 18 years old, (2) s/p OHT > 1 year, (3) not currently being treated for 
cancer, (4) has access to either phone line or mobile phone. The exclusion criteria included (1) 
cognitively impaired individuals, (2) non-English speaking. 
Those who fit the inclusion criteria were approached by the student to join the study. A 
total of 43 patients were approached, but only 41 (95%) consented to join the study.  One (1) 
patient declined to join while the other one (1) was too sick to have consented. 
Study Design 
The convenience sample of consenting adult heart transplant participants (n= 41) was 
randomly divided into the control (n = 20) and intervention (n=21) groups.  The intervention 
group received standard care plus follow-up phone calls at specific intervals specifically to 
remind them of de novo cancer screening. The control group received standard care.  
In order to measure the outcomes of this DNP Project, the student utilized The Time 
Series Design or sometimes called the Interrupted Time Series (ITS). The Time Series Design or 
ITS utilizes observations at multiple time points on a group or individual before and after an 
intervention to check whether the intended intervention had an effect (Campbell et al., 1963; 
Penfold et al., 2013;  Polit et al., 2004). Here, a string of consecutive observations equally spaced 
in time is interrupted by the imposition of a treatment or intervention (Harris et al., 2006). In this 
study, the DNP student placed a total of four phone calls space between 7-10 days to the 
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intervention group specifically for discussions regarding the importance of de novo cancer 
screening in the setting of immunosuppression. The control group received their routine care. 
Measurement Instrument 
The “Post Clinic Follow-up Phone Call Tool” (Appendix C) was designed by the DNP 
student specific to this project; it has not been tested before this project study. The design of this 
tool was patterned after the “How to Conduct a Postdischarge Follow up Phone Call” from the 
Re-Engineered Discharge (RED) Toolkit (RED, 2013). The tool served as a consistent guide for 
the DNP student during the intervention phase of the study specifically before, during and after 
the telephone follow-up. 
Implementation/Procedures 
The DNP student assembled a project team that included the DNP student as the project 
leader, a doctorally prepared faculty mentor from one public university in Western 
Massachusetts, and a doctorally prepared practice mentor from the project site. After the IRB 
approvals from both the public university (Appendix D) and project site were obtained, the DNP 
student proceeded with the implementation phase and data collection. The DNP student utilized 
the assistance of a statistician for guidance with the needed statistical computation. 
Data Collection/Implementation  
 The data collection and the implementation phase were divided into three phases: (1) the 
pre-intervention phase, (2) the intervention phase, (3) and the post-intervention phase. The pre-
intervention phase included the recruitment of participants. The intervention phase included the 
actual calling of the patient utilizing the principles of the Time Series design and the use of The 
Post Clinic Follow-up Phone Call Tool. The post-intervention phase included the data gathering, 
analysis, and interpretation. 
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Pre-Intervention phase. The pre-intervention phase included the recruitment of 
participants from November 26, 2018, to January 16, 2019, in the hours of 9 AM to 1 PM, 
Mondays to Thursdays. All patients were from the cohort of the DNP student who came for their 
routine, sick or post-hospitalization clinic visits. 
All recruited patients were done in a face to face fashion.  Once the patient expressed 
interest in joining the study, the student then explained the study in detail. Furthermore, the 
student also handed, read and explained to the patient the pre-printed statement in layman’s term 
(Appendix E), which explained the relationship between chronic immunosuppression and de 
novo cancer development.  At the end of the clinic encounter, signed consent was requested from 
the patient. Once the consent was obtained, the DNP student then proceeded to collect the 
needed data from the patients’ charts. The clinic questionnaire form was utilized as a guide 
(Appendix F). 
As noted above, 95% of the patients who were approached by the student consented to 
join the study.  At the end of the recruitment dates, the DNP student randomly divided the 
selected patients to the control group and the intervention group. To do this, the student wrote the 
individual name of each participant in a small piece of paper and then placed inside a brown 
paper bag. The student then mixed well the names inside the paper bag drawing the first 21 
names and assigned them to the intervention group. The remaining twenty names were assigned 
to the control group.  
Intervention phase. The intervention phase was from January 28, 2018, to February 27, 
2019. The control group did not receive any follow-up phone calls except at the last week of the 
intervention phase to ascertain whether the participants followed up or not with their cancer 
screening. The intervention group received a total of 4 calls at point intervals specifically to 
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remind them regarding de novo cancer screening. The patients took the opportunity to ask further 
questions and discussions. If attempts to speak with patients were unsuccessful, the student 
attempted to call 3 to 4 more times daily until contact was established. If after the third-day 
contact was not established, then the student waited until the next cycle.  
Preparing for the call.  Prior to calling the patients, the DNP student reviewed the 
participants’ demographics, preferences as to when and whom to call, health status and present 
illness.  The student also reviewed the diagnoses, plan of care, and in particular the discussion 
regarding follow up care with the relevant specialist for de novo cancer screening.  
Conducting the telephone follow-up call. The DNP student introduced himself and 
reminded the patient of the purpose of the call.  The student strictly followed the steps outlined in 
Follow-up Phone Calls, illustrated in Appendix C for accurate documentation and data 
gathering. “Have you seen or made a follow-up appointment with the required specialist”? 
“What made you do the follow up”? If the participant answered yes and provided a future date of 
appointment, then no further phone calls were made.  Those participants who did not see or made 
an appointment with a specialist, an analysis as to their possible reasons (transportation, weather-
related, busy, family reasons, recent hospitalizations and the like) were explored. Assistance was 
provided whenever it was applicable. For example, a number of the social worker was provided 
to the patient if it was necessary for transportation issues.  A discussion of the effects of chronic 
immunosuppression regarding de novo malignancy was also reinforced.  
Post-intervention phase. The post-intervention phase started on February 28, 2019, 
when all the telephone follow-up calls to both the intervention and control groups were 
completed. At this point, data were collected and analyzed to see whether the intervention was 
effective in prompting or motivating the heart transplant recipients to follow up with relevant 
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specialists for de novo cancer monitoring. Results from both the control and intervention groups 
were analyzed. 
Statistical Analysis 
An Excel spreadsheet was utilized for recording of collected data. The Statistical 
Program for the Social Science (SPSS, IBM Corp, Version 25) software was used for the 
analysis of the data.  The chi-squared analysis was performed to compare the percent of 
screening between the intervention and control group.  
Ethical Considerations/Protection of Human Subjects   
Strict adherence to the Health Insurance Portability and Accountability Act of 1996 
(HIPAA) was observed to ensure the confidentiality of the participant's Protected Health 
Information (HPI). All identifiable characteristics of the participants were eliminated. All 
electronic files containing identifiable information was password protected to prevent access by 
unauthorized users, and only the project leader had access to the said password. 
 All of the subjects were those who solely and freely volunteered to be participants; a 
copy of signed consent was provided to each participant. All subjects were educated about the 
consent and were advised multiple times that withdrawal from the project at any point in time 
will have no repercussions. Risks and benefits were explained to the subjects; there was no 
potential health risk expected from the project. No monetary compensation was provided to the 
participants; likewise, there was no associated cost from the participants as well. The data 
gathered after the study was destroyed per the institution policy. 
Result 
Socio-Demographics of Study Participants  
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The total sample size of the study was 41 (control group n=20; intervention group n= 
21). The mean age of the total population size was 60.3 (SD=12.36). Among the total 
participants, 32 (78%) were male, and 9 (22 %) were female.  There were 26 (63 %) White, 9 
(22%) Black, and 2 (5%) Hispanic, Asian and others respectively.  9 (22%) participants were 
single, 29 (71%) were married, and 3 (7%) were divorced. Of these participants, 3 (7%) had 
elementary schooling, 10 (24%) were high school graduates, 7 (17%) had some college degree, 
13 (31%) finished college and 8(20%) obtained graduate school degrees. Employment wise, 18 
(44%) participants are still working, 10 (24%) are disabled and 13 (32%) are retired. Income 
wise, 2 (5%) indicated an income between $10,000 - $30,000, and 39 (95%) stipulated an 
income more than $30,000 annually. Table 1 in Appendix G outlines the specific socio-
demographic profiles between the two groups. 
History of Illness 
The history of illness was limited to include only whether the patient had malignancy 
before or after transplantation, history of rejection (cellular or antibody mediated), other solid 
organ transplantation and number of years from initial transplantation. From the total population, 
31(76%) participants had no history of cancer and 10 (24%) had a past medical history of cancer 
prior to heart transplantation. 30 participants (73%) had no history of cellular or antibody-
mediated rejections, while 11 (27 %) had a history of either cellular or antibody-mediated 
rejections. 2 (5%) of the participants had two solid organ transplantations while the rest (39%) 
only had a heart transplant history. 16 of these participants (39%) were recently transplanted 
between 1-5 years, 8 (20%) were transplanted between 5-10 years, 11 (27%) between 10-15 
years, and 6 (14.6 %) between 15-20 years. None of the participants were beyond twenty years 
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of post-heart transplantation.  Table 2 in Appendix H outlines in detail the comparison of the 
history of illness between the control and intervention groups.   
Intervention Group Follow-up Phone Calls 
Multiple calls at time intervals between 7-10 days were placed to the intervention group 
from January 28, 2019, thru February 27, 2019. 
First phone call. The participants in the intervention group received their first call on 
January 28, 2019, thru January 30, 2019. All answered the call except for one who was outside 
of the country at that time. One participant was removed from the study due to recurrence of 
malignancy. One patient already saw a specialist attributing the reason for the follow-up to the 
earlier specific discussion about the possible increased risk of de novo malignancy among heart 
transplant patients. 2 (11%) participants indicated that they were not able to see a specialist due 
to weather-related issue, 10 (56%) participants said they were busy, 3 (17%) indicated that they 
forgot, and another 3 (17%) participants stated that were either recently discharged from the 
hospital or were dealing with other health issues (Appendix I). 
Second phone call. The intervention group received the second cycle of calls from 
February 6, 2019, thru February 8, 2019.   During the second cycle of the phone call, two 
participants were not reachable by phone. One participant was able to obtain a specialist 
appointment on April 3, 2019. In addition, 5 of the participants (27.2%) saw the specialist. At 
this point in time, there were already a total of 6 participants who saw the patient.  All of these 6 
participants including the one who made the appointment on April 3, 2019 indicated that the 
reason for their decision to seek de novo cancer screening was because of the discussions during 
the first phone call. Those who did not see the specialist or made an appointment stipulated that 
they all want to see a specialist except for one person who had difficulty walking at that time. 
DE NOVO CANCER MONITORING FOR ADULT HEART  25 
 
The different reasons why the other participants did not see a specialist is illustrated in Appendix 
J. 
Third phone call.  The third cycle of follow-up phone call started on February 16, 
2019, to February 19, 2019. At this time one more participant saw a specialist attributing the 
reason for their follow-up to the earlier discussions regarding the development of de novo 
malignancy among solid organ recipients. During this time, nobody indicated “forgetting” as the 
reason for not following up with a specialist. Of the remaining participants, 2 individuals (25%) 
indicated that insurance related issue or requirement prevented them from seeing the specialist, 
(i.e., they need to see their PCP first), 3 (37.5%) stated that recent hospitalization prevented them 
from seeing a specialist, 2 patients (25%) indicated family reasons, and 1 (12.5%) individual 
stated that having lots of things to do (busy) was the reason for not seeing a specialist. At this 
time there was no weather-related issue that was indicated by the participants as the reason for 
not following up with a specialist. All participants who did not see or make an appointment 
indicated that they all have the intent to see a specialist at some point due to the prior discussions 
(Appendix K). The same two participants, who did not respond during the second cycle, neither 
answered the phone calls again nor returned the requested messages for a callback. The student 
removed the two participants from the study. 
Fourth call. The fourth call was placed on February 27, 2019. This was the last phone 
call for the intervention group. At this time 2 additional participants saw the specialist citing the 
discussions on prior phone calls as a motivating factor for early cancer de novo screening. One 
participant indicated a scheduled specialist appointment during the second week of April. Those 
who were not able to see a specialist or make an appointment stipulated: 1 participant (14%) due 
to insurance issues, 2 participants (28%)- busy, 1 participant (14%)- due to recent hospitalization 
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or dealing with other current health issues, and 3partcipants (42%) cited family issues (Appendix 
L).  
Control Group Follow-up Phone Call 
The participants in the control group received one phone call from February 25, 2019,  to 
February 27, 2019, to check whether they followed up to see a specialist for de novo cancer 
monitoring or screening. 3 participants (15%) stated that they saw a specialist. All three 
participants indicated that the specific discussion solely geared towards cancer screening during 
their last clinic visit motivated them for de novo cancer screening.  
Two participants in the control group did not respond or call back within the allotted 
time. They were removed from the study. One participant underwent chemotherapy treatment 
and was also removed from the study. Of the remaining participants in the control group, 14 
(82.3%) did not see a specialist or make any appointment for de novo cancer screening. 
However, all of them indicated that they will follow up with a specialist in the near future for de 
novo cancer screening. Out of these 14 participants, 4 (28.5%) patients indicated that they were 
busy; 8 patients (57%) stated that they forgot, and 2 patients (14%) indicated that they just left 
the hospital (Appendix M).  
Comparison of Intervention vs. Control Group  
The intervention resulted in a statistically significant difference (χ2 (1) = 4.062, 
p=0.044<.05) between the control and the intervention groups for timely cancer screening. 
Patients in the intervention and control groups differed significantly in their cancer screening 
follow-up with a specialist.  The intervention group had a 50% follow-up with a specialist 
compared to the 15% follow up-rate of the control group. Please refer to the Chi Square Table in 
Appendix N. 
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Discussion 
The literature review showed that despite the current knowledge regarding the increased 
risk of cancer development among solid organ recipients (e.g., heart), cancer screenings are not 
done routinely or aggressively (Turkeli et al., 2016). Solid organ recipients (e.g., heart) who 
receive a later diagnosis of cancer compared to an early diagnosis have poorer outcomes 
compared to those who had early identification and treatment (Collins et al., 2012).  
The evidenced-based intervention for this study was the utilization of follow-up phone 
calls among adult heart transplant recipients. The assumption of the study was that multiple 
follow-up phone calls as an intervention would prompt heart transplant patients for an 
individualized cancer screening specific to their health situation. As was mentioned earlier, 
various studies showed that follow-up phone calls resulted in increased patient satisfaction, 
reduced emergency room or hospital re-admissions, and, improved adherence with the plan of 
care, (Biese et al., 2014; Dudas et al., 2001; Fenerty et al., 2012;  Harrison et al., 2011).  This 
was also affirmed by other studies such as the Cochrane Systematic Review indicating an 
improved in adherence to post-discharge appointments (Mistiaen & Poot, 2006; Soong et al., 
2014).  Furthermore, Patients consider the information they received from the telephone follow-
up as valuable (Beaver, Twomey, Witham, Foy, & Luker, 2006) and thus by the reinforcement of 
information results in increased compliance to instructions (Beaver, Twomey, Witham, Foy, & 
Luker, 2006). 
The result of this DNP study does seem to also affirm the above-cited studies.  The 
statistical analysis on this project showed a significant difference in the number of follow-up rate 
with a specialist between the intervention (50%) and control groups (15%), Chi square: 2 = 
4.062,  df = 1 p=0. 044. Moreover, it is worth noting that within the period of the intervention 
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phase, two other participants in the intervention group had set appointment dates with a 
specialist. They were not included in the total tally of those who actually saw the specialists, 
because they were outside of the intervention phase period. So had the intervention phase been 
scheduled up to the second week of April, then those who have seen the specialist would have 
been up to 61%.  In contrast, while 15% of the participants in the control group saw the 
specialist, no one of those who did not see the specialist made any future appointment.  
In this study, the intervention group received a total of four phone calls. Each phone call 
to every participant did not only include a reminder for him or her to follow-up with a specialist 
but more so a discussion and counseling regarding the effects of chronic immunosuppression 
state to one’s overall health. The follow-up phone calls provided the participant and the DNP 
student an opportunity for a thoughtful and individualized discussion regarding the participant’s 
specific cancer screening and other health or medical needs. 
All participants who either saw a specialist or made an appointment in the near future 
indicated that the motivating factor for them was the follow-up phone calls along with the 
discussion and counseling that went with it. It is worth noting that all participants who did not 
see a specialist or made an appointment, in both the intervention and control groups did verbalize 
the importance of cancer screening for de novo malignancy. Not one of these participants in the 
control or intervention group indicated that cancer screening was not important or necessary.  
The most indicated reasons why the participants did not see a specialist were:  (1) weather- 
related, (2) insurance issue, (3) busy, (4) forgot, (5) recent hospitalizations, and (5) family 
reasons.  
Unlike the control group which received only one phone call (Appendix M), the 
frequencies and the percentages of the above-noted reasons in the intervention group varied from 
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the first thru the fourth telephone calls. For example, the percentages of those who stated that 
they “forgot” to follow-up were higher in the first and second calls compared to the third and 
phone calls. Likewise, compared to the first and second calls, there was an increase in the 
number of “family issues” as a reason why the participants did not see a specialist during the 
third and fourth calls which fell during around the President’s Day. Several of the participants 
were away with their family on a short vacation trip. The different tables in Appendices I thru L 
illustrate in detail the above point.  Future research may be indicated to explain the variances of 
these responses.  
Practice Implications 
 Repeated telephone follow-up calls as an intervention after a patient’s clinic visit is a 
feasible form of patient contact to support continuity of care in the outpatient area. It does seem 
to appear from this particular study that the individualized follow-up phone calls of a nurse 
practitioner yielded positive results regarding the patients’ compliance with cancer screening. 
For complex patients with extensive health history, a more intensive intervention like repeated 
phone calls may be necessary (Burke & Coleman, 2013; Soong et al., 2014).  As providers 
amidst the budgetary cuts and economic climate, nurse practitioners are uniquely positioned to 
conduct telephone calls for continuity of care (Hannan, 2012). 
Facilitators and Barriers   
The setting facilitators were the noted stakeholders above. The DNP student found that 
most of the staffs and cardiologists and other nurse practitioners were supportive of the study. 
The barriers that were experienced by the student were (1) skepticism by a few of the staff 
members, (2) lack of time or shortage of internal resources such as staffing issues and, (3) 
resistance to change.  According to Henderson (2012), transferring research findings into clinical 
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practice is a slow process, and the uptake is variable and haphazard.  As stated earlier, the 
approach regarding discussion and follow-up regarding de novo malignant development among 
heart transplant providers varies from one provider to another. Implementing a protocol change 
regarding the aforementioned may be particularly challenging, and may be hindered by 
broad factors such as the organizational culture, external policy drivers, and health professional 
perceptions of the problem or style of management (Henderson, 2012).   
Limitation of the Study 
There are several limitations to this study. First, the subject population is small and was 
carried in one Transplant Center Only. Second, the student had minimal clinic days during the 
recruitment phase due to the major holidays (Thanksgiving, Christmas, New Year). This in part 
affected the number of recruited participants. Furthermore, the intervention phase also fell after 
the New Year and the President’s day where several of the participants were away on vacation. 
This affected in part some of the participants’ responses to the follow-up phone calls, and also in 
making the necessary appointments to the specialists. Third, another limitation of this study was 
time. The intervention phase was only done in 31 days. The follow-up phone calls which were 7-
10 days apart may have been too close to one another. Fourth, the “follow-up phone call tool” 
which the DNP student utilized as a guide during the intervention phase has not been tested in 
prior studies. Some of the verbiage used as a reason for not following (e.g., busy, family issues) 
may be overlapping. It needed more definition.   
Study Strengths 
The organization where the study was done supports research studies for improvement in 
the excellence of patient care. The above-noted stakeholders were also supportive of the study.  
As was noted earlier, all the participants were from the cohort of patients of the DNP student. 
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The student has been their provider for at least five years. Therefore, a certain level of trust had 
been established already.  
Furthermore, the participants were more responsive when contacted by the student. 
However, given the fact that the participants are patients of the DNP student, it is worth noting 
that during the recruitment and intervention phases of the study, careful consideration was 
observed to avoid soft coercion for the participants to either join or continue with the study. The 
participants were reminded many times that there would be no repercussions or explanations 
required if they decided not to participate or stay with the study.  However, it is noteworthy to 
mention that the majority of those who consented verbally expressed their desire to freely join 
the project as their small contribution to the second chance in life. 
Cost-Benefit Analysis/Budget 
The cost of this DNP project was minimal (Appendix N). The student was the leader of 
the project.  The student and the stakeholders are also employees of the heart transplant program 
and therefore incurred no additional expenses during the meeting sessions before, during and 
after the study. The student utilized the free services of a statistician.  All participants were 
voluntary; there were no monetary payments or benefits provided to them. 
Given the positive result of the study, the potential benefit of this project is substantial 
both in terms of human life and financial savings from the hospital and the overall healthcare 
system. Supposing that if a conservative estimate of only 25% (instead of the 50%) who 
followed up with a specialist were diagnosed with a de novo malignancy in their early stages, 
then these would translate to early modulation of their immunosuppression and intervention of 
the specialists. These would translate to about 17, 299 number of patients from the total heart 
transplant patients noted from the recent national data of UNOS. One can then presuppose that 
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these conservative estimate of 17, 299 patients may have a potentially limited hospital admission 
compared to a complicated full-blown malignancy admission in the setting of chronic immuno- 
suppression.   
There are many complications that full-blown cancer can bring about in heart transplant 
patients given their immunosuppression state. One example of many is septicemia, which would 
now require the services of other specialists, a critical care unit bed, and services, thus escalating 
higher potential costs.  Septicemia was the most expensive condition treated in 2013 accounting 
for 23.7 billion dollars (Torio & Moore, 2016). Furthermore, re-admissions occurring after 
severe sepsis is commonly occurring within the first 30 days; incurring significant mortality and 
cost (Goodwin, Rice, Simpson, & Ford, 2015). The point here is not to highlight that heart 
transplant recipients’ hospitalizations are either septicemic or fatal, but that the simple preventive 
measure proposed by this DNP project could potentially benefit others by avoiding such 
staggering human and financial costs. 
Conclusion  
  The purpose of this project was to examine the effectiveness of multiple follow-up 
phone calls placed as an intervention several days after the clinic visits of adult heart transplant 
recipients.  The result of the study showed that repeated telephone follow-up calls are feasible as 
an intervention after the patient’s clinic visit to support continuity of care in the outpatient 
setting. The intervention yielded a positive result showing an increase in de novo cancer 
screening among the participants in the intervention group compared to the control group. These 
positive findings are similar to the different studies noted earlier regarding the benefits of 
telephone follow-up care.  This may be related to the fact that the heart transplant recipients had 
DE NOVO CANCER MONITORING FOR ADULT HEART  33 
 
the opportunity to ask more deliberate and thoughtful questions, and the student to counsel and 
further discuss with them their individualized and specific plan of care.   
The result of this DNP Project supports that multiple follow-up phone calls as an 
intervention can bring about positive effect on these heart transplant recipients with complex 
health issues. Early identification of de novo malignancy is critical because it could provide the 
transplant team at the time of diagnosis, the ability to modulate early the immunosuppression 
regimen in collaboration with the treatment plan of the specialist. This is to avoid further 
complications in what is already a complicated medical condition, thus avoiding unnecessary 
human sufferings and financial cost. 
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Appendix A 
National Data 
Transplants by Organ Type January 1, 1988 - January 31, 2018 
Based on OPTN data as of February 18, 2018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: 2018 United Network for Organ Sharing, a non –profit 501 (c) (3) organization 
https: //unos.org/data/transplant-trends/transplants-by-organ-type 
Kidney
Liver
Pancreas
Pancreas/Kidn
ey
Heart
Lung
Heart/Lung
 
Organ Transplants 
Total 724,355 
Kidney 426,842 
Liver 156,587 
Pancreas 8,577 
Kidney / Pancreas 22,967 
Heart 69,198 
Lung 36,003 
Heart / Lung 1,232 
Intestine 2,921 
Abdominal Wall 1 
Head & Neck: 
Craniofacial 
5 
Head & Neck: Scalp 1 
GU: Penile 1 
GU: Uterus 10 
Upper Limb: Bilateral 6 
Upper Limb: Unilateral 4 
Total 724,355 
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Appendix B 
Dorothea Orem Self Care Theory Diagram 
 
 
        
 
 
 
 
                                                  
 
 
 
Source: https://nurseslabs.com/dorothea-orems-self-care-theory 
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Appendix C 
Post Clinic Follow-up Phone Calls 
 
 
Intervention Group: _____ 
Control Group: _____ 
 
Date of Phone Call: _____________________ 
Pt Initials: ____________________________ 
MRN: _______________________________ 
Number of Phone Calls: _________________ 
Patient Terminated Participation: ____ (Thank the patient for his/her time.)  
 
Phone Call: 
• Hello Mr./Ms./Mrs. _____________________________. I am Angelo C. Mabasa, DNP 
student.  I spoke to you about ____________ days or weeks ago. As discussed, I am 
calling you to follow up regarding the cancer screening we spoke about. 
 
• May I continue?  → If the patient does not wish to continue, politely inquire if he or she 
wants to drop out of the study; if not ascertain the best time to call back.  
 
• If the patient wishes to continue with the phone call; proceed with the following 
questions: 
 
➢ Have you seen any doctor/provider/specialist specific to cancer screening? 
 
➢ If yes:  
o When did you make the phone call? ___________________________________ 
o When did you actually see the specialist? _______________________________ 
o What made you do the follow up? ____________________________________ 
o Thank you for participating in the study. I will no longer call you back.  
 
➢ If No: 
o Can you tell me why you were not able to follow up with the 
specialist__________________________________________________________? 
(e.g. busy, family reasons, forgot, recent hospitalizations, others) 
 
o Or  
o Was it due to a transportation issue? (If yes, provide the phone number of the 
cardiac transplant social work department XXX-XXX-XXXX) 
o Was it due to a weather-related issue? 
o Was it due to a monetary issue?  
o Was it due to a work-related issue? 
o Was it due to the insurance issue? (If yes, provide the phone number of the 
Cardiac transplant social work department XXX-XXX-XXXX) 
o Was it because you did not think it was important to follow up? 
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o Other reasons: (e.g. Cultural, intentional or inadvertent reasons, etc.) 
________________________________________________________ 
 
 
➢ REINFORCE EFFECT OF IMMUNOSUPRESSION ON DE NOVO CANCER 
DEVELOPMENT. THEN ASK THE PATIENT IF HE/SHE HAS ANY 
QUESTION. 
 
 
➢ Remind patient that you will be calling again in 7-10 days if acceptable. 
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Appendix D 
IRB Letter of Approval University of Massachusetts Amherst 
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Appendix E 
Chronic Immunosuppression and De Novo Cancer Development 
 
 
 
 
 Hello Mr./Ms./Mrs. ___________________. Thank you for participating in this study. 
As you well know, you are taking immunosuppressive medications to avoid rejection of your 
transplanted heart. 
 
These immunosuppressive medications (Neoral or Cyclosporine; Prograf or Tacrolimus; 
Cellcept or Mycophenolate; Myfortic; Rapamune or Rapamycin; Everolimus or Zortress; or 
others which are not mentioned here) reduces your body's ability to fight against many things 
including cancer cells. Recent studies showed that solid organ recipients (example heart) 
have a 2-3 increased risk of developing de novo (or new) cancer in their lifetime.   
 
 
It is therefore crucial that you keep a regular cancer screening schedule follow-up with 
other providers so that early development of any cancer is detected early. These providers or 
specialists may be your dermatologist (skin), gastroenterologist (stomach), urologist (prostate), 
hematologist (blood), nephrologist (kidney) and others. 
 
If you have not made any appointment or gone to see any of the above specialist/s, it is 
highly recommended that you follow up sooner rather than later for reasons noted above. 
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Appendix F 
Clinic Questionnaire Form 
 
Intervention Group: ___ 
Control Group: ___ 
 
Today’s Date:  __________________  
Name:   ______________ (Initials Only) 
MRN:  ____________________ (Will be completed by the project study leader) 
Sex: (Please choose one by indicating a check “ ” mark.) 
o Male      ____ 
o Female   ____ 
Age: _____________ 
 Race: (Please choose one by indicating a check “ ” mark.) 
o White ___ 
o Black ___ 
o Hispanics ___ 
o Asian ___ 
o Others ____________________________________________ 
Reason for Visit: (Please choose one by indicating a check “ ” mark.) 
o Sick Visit ___ 
o Routine     ___ 
o Others:      ___ 
Education (Please choose your highest level of education by indicating a check “ ” mark.) 
o High school Graduate ___ 
o College graduate ___ 
o Graduate School ___ 
o Other: ________________________________________ 
Employment: (Please choose one by indicating a check “ ” mark.) 
o Profession ____ 
o Retired:    _____ 
o Others (e.g. disability) ___________________________ 
Date of Transplant (Please provide the date) (If you do not remember the exact date, the project 
leader will check in your chart) 
o Heart (#1)      __________________________________ 
o Heart (#2)      __________________________________ 
o Other Organs __________________________________ 
 
Providers: (Please write the names and their field of expertise) 
DE NOVO CANCER MONITORING FOR ADULT HEART  48 
 
o PCP: __________________________________________ 
 
o Specialists: (dermatologist, gastroenterologist, urologist, dentist, endocrinologists, others) 
_______________________________________________ 
 
o Others: _________________________________________ 
 
Telephone: (Please list in order of preference) 
o Mobile   ____________________________________ 
o Landline ____________________________________ 
Preferred time to be called: (Kindly indicate your preferred time for a follow up phone call. I will 
try to stay close to it as best as possible.) 
o _______________________________________________ 
 
 
Thank you for participating in this DNP Project Study. 
Angelo C. Mabasa, NP.C 
DNP Student 
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Appendix G 
Table 1 
 
 
Table 1 
Sociodemographic Profile of the Intervention and Control Groups 
  
Intervention Group (n=21) 
n (%) 
 
Control Group (n=20) 
n (%) 
 
Gender 
Male 
Female 
 
 
16 (76.2%) 
5 (23.8%) 
 
16 (80%) 
4 (20%) 
 
Race 
White 
Black 
Hispanic 
Asian 
Others 
 
 
13 (61.9%) 
4 (19.0%) 
1(4.8%) 
1 (4.8%) 
2 (9.5%) 
 
13 (65%) 
5 (25%) 
1 (5%) 
1 (5%) 
 
 
Marital Status 
Single 
Married 
Divorced 
 
 
5 (23.8%) 
15(71.4%) 
1 (4.8%) 
 
 
4 (20%) 
14 (70%) 
2(10%) 
Education 
Elementary School only 
HS Graduate 
Some College 
College Grad 
Graduate School 
 
1(4.8%) 
   5(23.8%) 
4 (19%) 
   7 (33.3%) 
4 (19%) 
 
2 (10%) 
5 (25%) 
3 (15%) 
6 (30%) 
4 (20%) 
Employment 
Currently Working 
 
9 (42.9%) 
 
9 (45%) 
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Disabled 
Retired 
 
6 (28.6%) 
6 (28.6%) 
4 (20%) 
7 (35%) 
Income 
>$ 30,000 
< $ 30,000 
 
21 (100%) 
 
18 (90%) 
2 (10%) 
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Appendix H 
Table 2 
 
Table 2.  
Limited History of Illness of the Intervention and Control Groups 
  
Intervention Group(n=21) 
n(%) 
 
 
Control Group (n=20) 
n (%) 
Cancer History                  Yes= 4 (19%) 
No= 17(80.9%) 
   Yes= 6 (30%) 
     No= 14 (70%) 
Rejection History* Yes= 5 (23.8%) 
No= 16 (76.2%) 
                Yes= 6 (30%) 
                No= 14 (70%) 
 
Number of Years with 
cancer? 
 1-5=    9 (42.9%) 
                  5-10= 2 (9.5%) 
10-15= 4 (19%) 
   15-20= 6 (28.6%) 
                   >20 =  0 
     1-5=  7 (35%) 
      5-10= 6 (30%) 
      10-15=7 (35%) 
                15-20= 0 
       >20= 0 
 
*Rejection History includes and/or antibody mediated rejection 
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Appendix I 
First Call Intervention Group 
 
 
Table 3 
Intervention Group Reason’s for not following up with a specialist-First Call. 
Intervention Group (N= 21) 
                  Frequency Valid Percent 
Did not think it was important 0  
Transportation Issue 0  
Weather Related 2 11.1 
Insurance Issue 0  
Busy 10 55.6 
Forgot 3 16.7 
Recent Hospitalization 3 16.7 
Family Reasons 0  
Total  100% 
*1 patient saw specialist already at first follow up phone call. 
*1 patient was outside the country 
*1 patient did not answer the call 
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Appendix J 
Second Call Intervention Group 
 
Table 4 
Intervention Group Reason’s for not following up with a specialist-Second Call. 
Intervention Group (N= 21) 
                  Frequency Valid Percent 
Did not think it was important 0  
Transportation Issue 0  
Weather Related 0  
Insurance Issue 2 15.4 
Busy 6 46.2 
Forgot 1 7.7 
Recent Hospitalization 1 7.7 
Family Reasons 3 23.1 
Total  100% 
*5 patients saw specialist at second follow-up phone call. 
*1 patient made an appointment on April 3, 2019 
*1 excluded from study during the second call due to de novo malignancy development 
*Total number of patients who saw specialist= 6 patients 
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Appendix K 
Third Call Intervention Group 
 
Table 5 
Intervention Group Reason’s for not following up with a specialist-Third Call. 
Intervention Group (N= 18) 
                  Frequency Valid Percent 
Did not think it was important 0  
Transportation Issue 0  
Weather Related 0  
Insurance Issue 2 25.0 
Busy 1 12.5 
Forgot 0  
Recent Hospitalization 3 37.5 
Family Reasons 2 25 
Total  100% 
*1 patient saw specialist at third follow-up phone call. 
*2 patients removed from the study for failing to answer more than two phone call cycles.  
*Total number of patients who saw specialist= 7 patients 
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Appendix L 
Fourth Call Intervention Group 
 
Table 6 
Intervention Group Reason’s for not following up with a specialist-Fourth Call. 
Intervention Group (N= 18) 
                  Frequency Valid Percent 
Did not think it was important 0  
Transportation Issue 0  
Weather Related 0  
Insurance Issue 1 14.3 
Busy 2 28.6 
Forgot 0  
Recent Hospitalization 1 14.3 
Family Reasons 3 42.9 
Total  100% 
*2 patients saw specialist at fourth follow-up phone call. 
*1 patient made an appointment for second week of April 2019. 
*Total number of patients who saw specialist= 9 patients 
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Appendix M 
One Call to Control Group 
 
Table 7 
Control Group’s Reasons for not Following up With a Specialist 
Control Group (N=20) 
 Frequency Valid Percent 
Did not think it was important 0  
Transportation Issue 0  
Weather Related 0  
Insurance Issue 0  
Busy 4 28.6 
Forgot 8 57.1 
Recent Hospitalization 2 14.3 
Family Reasons 0  
Total  100% 
*3 Patients saw Specialist 
*1 Patient excluded from the study due to malignancy recurrence 
*2 Patients did not answer the call. Excluded from the study. 
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Appendix N 
Chi Square Table  
Intervention and Control Group 
 
   Group   
Saw 
Specialist?  
 Intervention 
group  
 Control group Total 
Yes Observed   
frequency 
9 3 12 
 Expected 
frequency  
6.2 5.8 12 
No  Observed   
frequency 
9 14 23 
 Expected 
frequency  
11.8 11.2 23.0 
Total Observed   
frequency 
18 17 35 
 Expected 
frequency  
18.0 17.0 35.0 
2 = 4.062,  df = 1 p=0. 044 
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Appendix O 
Actual Cost of the DNP Project 
 
 
Item Description Quantity/Unit Cost Total Amount 
Typing Paper 2 Units $ 8.00 $16.00 
Laser Printer 
Cartridge 
1 Cartridge $ 90.00 $90.00 
Statistician Fee  Free $0.00 
Student Time < > ~ 600 hours $ 0 $0.00 
Cell Phone 1 (Old Phone of the 
DNP Student) 
$ 0 $0.00 
Monthly Fee for the 
Cell Phone (Cricket) 
Talk and Text no data 
access 
~1 month $ 25.00 $25.00 
Sim Card 1 $10.00 $10.00 
Donations 0 0 0 
Total Cost   $141.00 
 
